160 related articles for article (PubMed ID: 1523100)
21. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
22. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
[TBL] [Abstract][Full Text] [Related]
23. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
[TBL] [Abstract][Full Text] [Related]
24. Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP.
Kaufmann JE; Oksche A; Wollheim CB; Günther G; Rosenthal W; Vischer UM
J Clin Invest; 2000 Jul; 106(1):107-16. PubMed ID: 10880054
[TBL] [Abstract][Full Text] [Related]
25. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
26. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
27. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
28. Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease.
Casonato A; Sartori MT; Pontara E; Bertomoro A; Dannhäuser D; Girolami
Blood Coagul Fibrinolysis; 1991 Aug; 2(4):567-73. PubMed ID: 1768767
[TBL] [Abstract][Full Text] [Related]
29. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
Greer IA; McLaren M; Belch JJ; Lowe GD; Forbes CD
Haemostasis; 1986; 16(1):15-9. PubMed ID: 3084364
[TBL] [Abstract][Full Text] [Related]
30. Studies on the prolonged bleeding time in von Willebrand's disease.
Mannucci PM; Pareti FI; Holmberg L; Nilsson IM; Ruggeri ZM
J Lab Clin Med; 1976 Oct; 88(4):662-71. PubMed ID: 787458
[TBL] [Abstract][Full Text] [Related]
31. Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry.
Giannini S; Mezzasoma AM; Leone M; Gresele P
Haematologica; 2007 Dec; 92(12):1647-54. PubMed ID: 18055988
[TBL] [Abstract][Full Text] [Related]
32. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
[TBL] [Abstract][Full Text] [Related]
33. [Impaired fibrinolytic response to the venous occlusion test in patients with cryptogenic colitis].
Gris JC; Schved JF; Raffanel C; Dubois A; Ribard D; Balmes JL
Gastroenterol Clin Biol; 1991; 15(12):933-8. PubMed ID: 1783249
[TBL] [Abstract][Full Text] [Related]
34. Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
Patrassi GM; Sartori MT; Casonato A; Viero ML; Pontara E; Saggiorato G; Girolami A
Thromb Res; 1992 Jun; 66(5):517-26. PubMed ID: 1523608
[TBL] [Abstract][Full Text] [Related]
35. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
[TBL] [Abstract][Full Text] [Related]
36. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
[TBL] [Abstract][Full Text] [Related]
37. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
38. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
Casonato A; Dannhauser D; Pontara E; Bertomoro A; Orazi B; Santarossa L; Zerbinati P; Girolami A
Blood Coagul Fibrinolysis; 1996 Jul; 7(5):549-53. PubMed ID: 8874865
[TBL] [Abstract][Full Text] [Related]
39. 1-Desamino-8-arginine-vasopressin corrects the hemostatic defects in type 2B von Willebrand's disease.
McKeown LP; Connaghan G; Wilson O; Hansmann K; Merryman P; Gralnick HR
Am J Hematol; 1996 Feb; 51(2):158-63. PubMed ID: 8579058
[TBL] [Abstract][Full Text] [Related]
40. Fibrinolytic capacity following stimulation with desmopressin acetate in patients with diabetes mellitus.
Grant MB; Fitzgerald C; Guay C; Lottenberg R
Metabolism; 1989 Sep; 38(9):901-7. PubMed ID: 2505017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]